Ambroxol

Description

Ambroxol induces activation of the surfactant system by acting directly on the type II pneumocytes of the alveoles and the Clara cells in the region of the small airways. It promotes the formation and outward transfer of surface-active material in the alveolar and bronchial region of the foetal and adult lungs.

Medicine classification

R05CB06

Ambroxol

R Respiratory system → R05 Cough and cold preparations → R05C Expectorants, excl. combinations with cough suppressants → R05CB Mucolytics

Medicines

ALPOSAN

Lithuania

AMBROBENE

Austria

AMBROHEXAL

Austria

AMBROLAN

Austria Lithuania

AMBRON

Hong Kong

AMBROSAN

Lithuania

AMBROSPRAY

Lithuania

AMBROTUSIN

Lithuania

AMGICOL

Hong Kong

AMPROMED

Hong Kong

AMSOL

Hong Kong

AMSOLVAN

Hong Kong

AMXOL

Hong Kong Singapore

APOXOL

Spain

AVENPHYL

Hong Kong

AXOL

Hong Kong Singapore

BRONTEX

Lithuania

BROXIVAN

Lithuania

BUCOXON

Spain

DINOBROXOL

Spain

EUROBROXOL

Hong Kong

FLAVAMED

Lithuania

FLUIBRON

Cyprus

FUCOVENT

Hong Kong

HALIXOL

Lithuania

HIVOTEX

Cyprus

LASOLVAN

Lithuania

LEANGROW

Hong Kong

LYSOSPRAY

Cyprus

MEDOVENT

Cyprus Hong Kong

MOTOSOL

Spain

MUBROXOL

Hong Kong

MUCERA

Hong Kong

MUCIBRON

Spain

MUCOANGIN

Austria Netherlands

MUCOBROX

Hong Kong

MUCOBROXOL

Cyprus

MUCOCLEAR

Singapore

MUCODRENOL

Hong Kong

MUCOSAN

Austria Spain

MUCOSOLVAN

Austria Cyprus Hong Kong Singapore

MUXIMED

Spain

MUXOL

France

NADOXOL

Hong Kong

POLIBROXOL

Singapore

SHINOXOL

Singapore

STREPSILS CHESTY COUGH

Hong Kong Singapore

SURBRONC

France

TALIPIEN

Hong Kong

VICKOSOLVON

Hong Kong

Other medications with this active ingredient in combination: MUCOSPAS

Product monographs

FLAVAMED HUSTENSAFT Oral solution

MPI, EU: SmPC

Usage: Next >

Ambroxol

Description

Medicine classification

Medicines

Product monographs

2D Molecule Structure

Unique Ingredient Identifier (UNII)

CAS Registry Number

SNOMED-CT